Clinical Trial Update: Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study of AZD2281 (olaparib) in patients with BRCA mutation-associated ovarian cancer or recurrent high-grade ovarian cancer, and in BRCA-mutant or trip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Carcinoma

Drugs mentioned

• AZD2281 (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Carcinoma, Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-08-12